Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 793 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05849038RecruitingPhase 2
Treating inflammation to improve depression in HIV
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
Atlanta, GeorgiaAges 18–65 - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05903742Recruiting
Standard care for hepatitis delta in the Netherlands
This trial focuses on improving and standardizing how hepatitis delta is cared for in the Netherlands. To take part, you must have confirmed active hepatitis delta and be an adult.
RotterdamAges 18 years+ - NCT05922306RecruitingEarly Phase 1
Testing continuous vs pulsed treatment for chronic hepatitis B
This early-phase study compares two ways of giving treatment for chronic hepatitis B: continuous antiviral therapy versus pulsed treatment. It may help find a schedule that works well and is tolerable for people with hepatitis B.
Hefei, AnhuiAges 18–60 - NCT05935826RecruitingPhase 3
Amino acids to reduce liver fat in teens with NAFLD
This study tests whether adding amino acids can lower fat stored in the liver of teens with non-alcoholic fatty liver disease (NAFLD). It may help improve liver health by changing how much liver fat is present over the study period.
Aurora, ColoradoAges 13–18 - NCT05950503Recruiting
MRI to assess liver spread from colon cancer
This trial studies how well MRI can evaluate liver metastases (spread to the liver) from colorectal cancer. If you have measurable liver lesions, your MRI results may help doctors better track and plan care.
RomaAges 18–85 - NCT05977283Recruiting
Follow-up study for people whose hepatitis B test improved
This study follows people with hepatitis B (HBV) blood tests that have improved over the last year. It aims to learn what happens after the hepatitis B surface antigen (HBsAg) goes down, and may help doctors better predict outcomes.
Guangzhou, GuangdongAges 18–65 - NCT05989958RecruitingPhase 1/Phase 2
HepaCure for acute-on-chronic liver failure
This trial tests a new treatment called HepaCure for people with acute-on-chronic liver failure (a sudden worsening of liver function in someone with long-term liver disease). The goal is to see if it is safe and can help improve liver function.
Beijing, Beijing MunicipalityAges 18–65 - NCT06051045Recruiting
Bulevirtide for chronic hepatitis B and D
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
StockholmAges 18 years+ - NCT06051513Recruiting
Testing colistimethate for CRE infection in hospitalized patients
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
Hefei, AnhuiAges 18–85 - NCT06078098Recruiting
Autoimmune Hepatitis Database and Biobank Study
This study is building a database and collection of samples from people with autoimmune hepatitis in Italy. It aims to learn more about the disease and improve care.
Monza, MBAges 1 year+ - NCT06122285Recruiting
Bulevirtide for chronic hepatitis delta
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
Milan, MIAges 18 years+ - NCT06154278RecruitingPhase 2
Testing imdusiran for chronic hepatitis B
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Baltimore, MarylandAges 18 years+ - NCT06179498Recruiting
Partner navigation for hepatitis C treatment in young people who inject drugs
This trial offers a partner navigation program to help young people who inject drugs and their main injecting partner work together to get treatment for hepatitis C (a liver infection).
San Francisco, CaliforniaAges 18 years+ - NCT06250309Recruiting
Mediterranean diet vs. Western diet for fatigue in AIH
This study tests whether a Mediterranean diet can reduce fatigue in people with autoimmune hepatitis (AIH) compared to a typical Western diet. You will receive frozen meals for a week and track your energy levels.
Indianapolis, IndianaAges 18–80 - NCT06263959RecruitingPhase 2
Testing a new hepatitis B pill (GST-HG131) for chronic HBV
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
BeijingAges 35–65 - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT06333561Recruiting
Combination therapy for infiltrative liver cancer
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06334497RecruitingPhase 3
Combination antiviral therapy for CMV in kidney transplant
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
ParisAges 18 years+ - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT06381453RecruitingPhase 2
Belimumab for autoimmune hepatitis
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
Calgary, AlbertaAges 18–80 - NCT06406049Recruiting
Finishing HIV prevention study
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
Miami, FloridaAges 18–54 - NCT06425341RecruitingPhase 2
Test injection to keep hepatitis B suppressed
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
Guangzhou, GuangdongAges 18 years+ - NCT06425380Recruiting
Resistant potato starch for liver cirrhosis and confusion
This study is testing whether a special type of starch (resistant potato starch) can help people with cirrhosis who have had episodes of confusion from liver problems. It may help by changing the bacteria in your gut, which could reduce the risk of future confusion episodes.
Rochester, MinnesotaAges 18–99
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 793 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.